Log in
OTCMKTS:POLXF

Polydex Pharmaceuticals Stock Forecast, Price & News

$1.07
+0.02 (+1.90 %)
(As of 11/25/2020 01:43 PM ET)
Add
Compare
Today's Range
$1.05
Now: $1.07
$1.07
50-Day Range
$0.91
MA: $1.04
$1.10
52-Week Range
$0.80
Now: $1.07
$1.23
Volume2,900 shs
Average Volume5,055 shs
Market Capitalization$3.67 million
P/E Ratio53.53
Dividend YieldN/A
Beta0.62
Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product to treat cystic fibrosis, a genetic disease. Further, it supplies ferric hydroxide and hydrogenated dextran solutions. Polydex Pharmaceuticals Limited sells its products through independent distributors and wholesalers, as well as directly to companies. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Industrial inorganic chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:POLXF
CUSIPN/A
Phone416-755-2231
Employees23

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.14 million
Cash Flow$0.15 per share
Book Value$1.75 per share

Profitability

Net Income$250,000.00

Miscellaneous

Market Cap$3.67 million
Next Earnings Date12/21/2020 (Estimated)
OptionableNot Optionable
$1.07
+0.02 (+1.90 %)
(As of 11/25/2020 01:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive POLXF News and Ratings via Email

Sign-up to receive the latest news and ratings for POLXF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions

How has Polydex Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Polydex Pharmaceuticals' stock was trading at $1.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, POLXF shares have increased by 0.9% and is now trading at $1.07.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Polydex Pharmaceuticals?

Wall Street analysts have given Polydex Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Polydex Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Polydex Pharmaceuticals' next earnings date?

Polydex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, December 21st 2020.
View our earnings forecast for Polydex Pharmaceuticals
.

How were Polydex Pharmaceuticals' earnings last quarter?

Polydex Pharmaceuticals Limited (OTCMKTS:POLXF) announced its quarterly earnings data on Tuesday, September, 15th. The company reported $0.02 EPS for the quarter. The business had revenue of $1.38 million for the quarter. Polydex Pharmaceuticals had a return on equity of 0.94% and a net margin of 1.16%.
View Polydex Pharmaceuticals' earnings history
.

Are investors shorting Polydex Pharmaceuticals?

Polydex Pharmaceuticals saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 900 shares, an increase of 28.6% from the September 30th total of 700 shares. Based on an average daily trading volume, of 5,900 shares, the days-to-cover ratio is presently 0.2 days.
View Polydex Pharmaceuticals' Short Interest
.

Who are some of Polydex Pharmaceuticals' key competitors?

Who are Polydex Pharmaceuticals' key executives?

Polydex Pharmaceuticals' management team includes the following people:
  • Mr. George G. Usher, Chairman, CEO & Pres (Age 61)
  • Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 67)
  • Mr. David P. Jamestee C.A., CPA, Chief Financial Officer (Age 54)

What is Polydex Pharmaceuticals' stock symbol?

Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."

How do I buy shares of Polydex Pharmaceuticals?

Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Polydex Pharmaceuticals' stock price today?

One share of POLXF stock can currently be purchased for approximately $1.07.

How big of a company is Polydex Pharmaceuticals?

Polydex Pharmaceuticals has a market capitalization of $3.67 million and generates $5.14 million in revenue each year. Polydex Pharmaceuticals employs 23 workers across the globe.

What is Polydex Pharmaceuticals' official website?

The official website for Polydex Pharmaceuticals is www.polydex.com.

How can I contact Polydex Pharmaceuticals?

Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.